Delusional Parasitosis (Ekbom Syndrome): The Unshakable Conviction of Infestation

The experience is vivid and unrelenting. Patients with delusional parasitosis (DP) describe crawling, biting, stinging, or burrowing sensations on or beneath their skin — sensations so concrete and distressing that no amount of reassurance or negative laboratory results can dislodge them. They inspect their skin for hours, sometimes with magnifying glasses. They dig at lesions, tweeze at fibers, and scrape at scabs, searching for the organism they are certain is there.

One of the most distinctive features in clinical practice is the "matchbox sign" (also called the "specimen sign" or "ziplock sign" in more contemporary accounts). Patients arrive at appointments carrying small containers — matchboxes, plastic bags, tape strips, jars — filled with material they have collected from their skin and environment. These specimens typically contain lint, skin flakes, dried blood, scab fragments, fabric fibers, or small environmental debris. Patients present them with conviction, expecting the clinician to identify the parasite. This sign is so characteristic that its presence should immediately raise clinical suspicion for DP.

The self-treatment patients undertake is often more damaging than the delusion itself. Many use bleach baths, kerosene, gasoline, industrial pesticides, or concentrated rubbing alcohol directly on their skin. They may scrub with abrasive materials until they bleed. Some fumigate their homes repeatedly, discard furniture, or move residences — only to find the "infestation" follows them. The resulting skin damage — excoriations, ulcerations, chemical burns, and secondary infections — constitutes dermatitis artefacta, self-inflicted skin injury that paradoxically reinforces the delusion: patients point to their wounds as evidence of the parasites' activity.

Social isolation is common. Patients may withdraw from family, refuse physical contact, launder clothing and bedding obsessively, and become consumed by the infestation to the exclusion of work, relationships, and basic self-care. The suffering is enormous and genuine.

DP has historically been considered rare, but contemporary estimates suggest it is more common than previously recognized — likely underdiagnosed rather than uncommon. A widely cited epidemiological estimate places the prevalence at approximately 27–30 cases per million population, though some dermatology centers report seeing several new cases per year, suggesting the true prevalence may be higher.

The classical demographic profile is well established: the condition peaks in women over age 50, often those who are socially isolated, widowed, or living alone. In many reported case series, the female-to-male ratio is approximately 2:1 to 3:1 in this older cohort. These patients typically have the primary form with no identifiable substance use or clear organic trigger.

However, clinicians now recognize a second demographic peak that has grown substantially over the past two decades: younger men (ages 20–40) with stimulant use disorders, particularly methamphetamine. In regions with high methamphetamine prevalence, emergency departments and dermatology clinics see this presentation regularly. The street terms — "meth mites," "crank bugs," "ice bugs" — reflect how common the phenomenon has become within stimulant-using populations.

A notable feature of DP is folie à deux (shared psychotic disorder), observed in roughly 5–15% of cases. A close family member — typically a spouse or adult child — comes to share the patient's conviction of infestation, sometimes presenting their own specimens. This shared form complicates treatment, as both individuals reinforce each other's beliefs.

The distinction between primary and secondary DP is clinically essential because secondary forms may resolve entirely when the underlying cause is treated.

Primary delusional parasitosis occurs without any identifiable organic or psychiatric cause. It is classified under the DSM-5 as delusional disorder, somatic type. Patients are typically otherwise cognitively intact and do not exhibit formal thought disorder. The delusion is circumscribed — outside the domain of the infestation, their thinking and functioning may appear entirely normal. This encapsulation is precisely what makes the condition so striking and so resistant to challenge.

Secondary to medical conditions:

• Diabetes mellitus — peripheral neuropathy produces genuine paresthesias that may be delusionally interpreted
• Vitamin B12 deficiency — causes peripheral neuropathy and psychiatric symptoms
• Hypothyroidism — associated with dry, pruritic skin and cognitive changes
• Hepatitis C and HIV — both through direct neurological effects and pruritic skin manifestations
• Lymphoma and other malignancies — paraneoplastic pruritus
• Prior actual parasitic infection — a resolved scabies or lice infestation can leave patients hypervigilant, with tactile misinterpretations persisting long after successful treatment

Secondary to substances:

• Methamphetamine and amphetamines — the most common substance-related trigger, driven by dopaminergic excess
• Cocaine — "cocaine bugs" or formication is well documented
• Prescribed medications — including corticosteroids, topiramate, ciprofloxacin, and dopamine agonists used for Parkinson's disease

Secondary to psychiatric conditions: DP-like presentations can occur in schizophrenia (as part of broader psychotic symptoms), severe depression (nihilistic or somatic delusions), and obsessive-compulsive disorder (though in OCD, insight is typically partially preserved).

Few conditions in contemporary medicine have generated as much acrimony between patients and the medical establishment as Morgellons disease. Patients describe multicolored fibers emerging from their skin, accompanied by crawling and biting sensations, fatigue, and cognitive difficulties they often call "brain fog." The term was coined in 2002 by Mary Leitao, a mother who observed fibers in her young son's skin lesions and named the condition after a 17th-century medical description.

A vigorous online patient advocacy community rapidly formed, lobbying the CDC for investigation. The CDC responded with a large-scale study conducted through Kaiser Permanente in Northern California, published in 2012. The investigation examined 115 case-patients and found no evidence of an infectious or environmental etiology. Fibers recovered from skin lesions were identified as cotton and other textile materials consistent with clothing. Skin biopsies showed no parasites or unusual pathogens. The study concluded that the condition was similar to delusional infestation.

The dermatological and psychiatric community largely considers Morgellons a variant of delusional parasitosis, distinguished mainly by the emphasis on fibers rather than organisms. However, this position has provoked intense anger from patient groups, some of whom point to research by Middelveen and colleagues claiming an association with Borrelia spirochetes (Lyme disease). These findings remain highly contested and have not been replicated by independent groups.

The debate illustrates a genuine clinical tension: dismissing patients' experiences as "just a delusion" fails them therapeutically and ethically, while endorsing an unsubstantiated infectious etiology risks unnecessary antibiotic treatment and delays effective psychiatric care. Clinicians must find a path between these extremes.

The neurobiological model with the most explanatory power centers on striatal dopamine dysfunction. Multiple lines of evidence converge on this mechanism:

First, the substances most strongly associated with secondary DP — methamphetamine, amphetamines, cocaine — are all potent dopamine agonists that increase synaptic dopamine, particularly in the striatum. The fact that dopaminergic excess reliably produces tactile hallucinations and parasitosis beliefs is strong indirect evidence for dopamine's central role.

Second, dopamine-blocking antipsychotics are the most effective treatment for DP. Pimozide, a first-generation antipsychotic with particularly strong D2 receptor blockade, was historically the drug of choice. The treatment response to dopamine antagonism essentially mirrors the provocation by dopamine agonism — a coherent pharmacological picture.

Third, neuroimaging studies in patients with somatic-type delusional disorders have shown alterations in prefrontal-striatal circuits involved in reality testing and sensory filtering. The striatum is a critical hub for filtering sensory input, and when its dopaminergic signaling is disrupted, normal background tactile sensations — the constant low-level activity of skin mechanoreceptors — may be amplified, misattributed, and incorporated into a delusional framework.

The insular cortex, which integrates interoceptive and exteroceptive body-related signals, is also implicated. Dysfunction here could explain why patients experience such vivid, somatically real sensations. The delusion is not merely a thought — it is felt in the body with a visceral intensity that makes it extraordinarily resistant to cognitive challenge. This is why telling patients "there's nothing there" is not only ineffective but experienced by them as a kind of gaslighting. Their sensory experience is real; its interpretation is delusional.

Antipsychotic medication is the evidence-based treatment for primary DP, and response rates are encouraging when patients can be engaged in treatment — with reported improvement in 60–90% of cases who maintain adequate medication trials.

Pimozide was long the first-line agent, supported by multiple case series. However, its use has declined due to significant safety concerns: QTc prolongation, risk of torsades de pointes, extrapyramidal side effects, and drug interactions via CYP3A4 inhibition. Current expert consensus favors second-generation antipsychotics:

• Risperidone (0.5–4 mg/day) — the most commonly recommended first-line agent in recent reviews
• Olanzapine (2.5–10 mg/day) — effective and well-tolerated in multiple case series
• Aripiprazole — increasingly used, with the advantage of lower metabolic side effects

The major treatment barrier, however, is not pharmacological but structural and relational. Patients with DP almost universally present to dermatologists, primary care physicians, or infectious disease specialists — not psychiatrists. Many have seen multiple physicians and have been told their skin is normal, which they interpret as medical incompetence. When psychiatric referral is suggested, the typical response is refusal or outrage: "I don't need a psychiatrist — I need someone to find what's crawling under my skin."

This means that dermatologists are often the clinicians who must initiate antipsychotic treatment, a task for which many feel unprepared. The growing subspecialty of psychodermatology addresses this gap, and collaborative care models involving dermatologists and psychiatrists working together show promise in improving engagement and outcomes.

The single most important clinical skill in managing DP is the ability to build a genuine therapeutic relationship without either endorsing the delusion or directly challenging it. Both extremes fail. Colluding — ordering unnecessary biopsies, prescribing antiparasitics, or pretending to find organisms — reinforces the delusional framework and delays effective treatment. Confronting — bluntly telling the patient "this is all in your head" — destroys the therapeutic relationship instantly and ensures the patient will never return.

Experienced clinicians describe a middle path. The approach involves several elements:

1. Validate the suffering, not the explanation. "I can see this is causing you tremendous distress. The sensations you're experiencing are real, and I want to help you get relief."
2. Examine the specimens respectfully. When patients present their matchbox, look at the contents carefully. Dismissing them without examination is experienced as dismissal of the person.
3. Perform a thorough workup — once. Complete a careful dermatological examination, relevant bloodwork (CBC, metabolic panel, B12, TSH, hepatitis serologies, HIV), and skin biopsy if clinically indicated. This demonstrates good faith and rules out secondary causes.
4. Frame medication in terms the patient can accept. Rather than saying "you need an antipsychotic for your delusion," effective clinicians may say: "This medication can help reduce the sensations you're feeling. It works on the nerve pathways that process skin signals." This is technically accurate and avoids the psychiatric framing that triggers refusal.
5. Maintain continuity. These patients have typically been dismissed by multiple providers. A clinician who continues to see them, listens to their concerns, and treats their skin injuries with appropriate wound care builds the trust necessary for medication adherence.

The suffering of these patients — socially isolated, disbelieved, often injuring themselves in attempts at self-treatment — deserves clinical seriousness and compassion, regardless of the etiology.